For Immediate Release
For more information, contact:
Cheri Winchester 636.530.3613
Clinical Testing Validates New Prostate Cancer Biopsy and Treatment Device
St. Louis, Mo. (July 7, 2005) - A recent study confirms that TargetScanT, a new FDA-approved targeted prostate biopsy and cancer-treatment system, delivers improved biopsies for the detection and treatment of prostate cancer.
The clinical test showed that TargetScan detected cancer more frequently upon the first biopsy than over conventional biopsy techniques. In the study performed on 20 prostatectomy specimens removed from men with prostate cancer, researchers simulated a TargetScan biopsy procedure and compared biopsy findings to those confirmed in final laboratory pathology conducted by an independent laboratory. The TargetScan biopsies identified the extent, location and the grade of cancer more accurately.
"The results of this study are statistically significant, validating the concept that TargetScan's approach to prostate biopsies can help physicians more accurately evaluate the prostate on the first biopsy and better characterize the extent and aggressiveness of cancer if it is found," said Dr. Gerald Andriole, professor of surgery and chief of urology at Washington University School of Medicine. "TargetScan biopsies should result in improved cancer detection-saving time, money and, potentially, lives."
Additionally, the researchers suggested that TargetScan's stabilized probe coupled with its ability to reproduce biopsies and intraprostatic needle localization could improve the success of new cancer-treatment deliveries, such as brachytherapy and cryotherapy.
About Envisioneering Medical Technology
Based in St. Louis, Mo., Envisioneering Medical Technologies is dedicated to developing, manufacturing and marketing proprietary diagnostic and treatment technology for the physician community. For more information, please visit www.envisioneeringmedical.com. |
